Promentis Pharmaceuticals has started dosing patients in a Phase II trial of SXC-2023 for the treatment of adults with moderate to severe trichotillomania.

Trichotillomania is a disabling condition caused by regular, uncontrollable hair pulling that results in hair loss.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The Phase II trial is designed to examine the safety, tolerability and efficacy of three oral doses of SXC-2023 in patients.

The double-blind, randomised trial is being conducted at 12 centres in the US.

It aims to enroll around 100 patients, who will be divided into three active-dose and placebo cohorts.

“SXC-2023 presents the possibility of a ground-breaking new therapy and commencing our Phase II trials is an important step towards that goal.”

The severity of trichotillomania symptoms, overall patient mental health and well-being, and other cognitive parameters will be assessed during the trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It will be followed by a Phase II add-on therapy trial evaluating SXC-2023 in obsessive-compulsive disorder.

Promentis Pharmaceuticals CEO Klaus Veitinger said: “We are very excited to commence our Phase II  programme, rapidly following our Phase I results showing SXC-2023 to be very safe, well-tolerated and with a well-behaved PK profile.

“SXC-2023 presents the possibility of a ground-breaking new therapy and commencing our Phase II trials is an important step towards that goal.

“The mechanism and excellent safety profile of the drug show great promise in a wide variety of impulse control and other disorders, as monotherapy and in combination with other treatments.”

Promentis is currently developing SXC-2023 to treat trichotillomania, obsessive-compulsive disorder, and neuropsychiatric diseases.